ACTG 219C: PEDIATRIC LATE OUTCOME PROTOCOL, VERSION 30 HIV/AIDS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 描述HIV感染婴儿、儿童和青少年的生存、生长、神经和神经心理功能、生活质量、器官系统毒性、代谢紊乱、机会性感染和恶性肿瘤的发展以及免疫学和病毒学参数随时间的晚期结局。这还将包括评价受试者接受的抗逆转录病毒和免疫治疗的潜在迟发效应、青春期影响以及并发症。本研究还将试图确定HIV感染妇女所生的未感染婴儿是否因在子宫内、围产期或婴儿早期暴露于抗逆转录病毒治疗或免疫治疗/疫苗而表现出任何短期或长期不良临床或实验室效应。 这是一项前瞻性纵向研究，对围产期HIV暴露婴儿、儿童和青少年以及在PACTG研究中心随访的围产期后获得性感染儿童进行长期随访，无论他们是否入组PACTG方案。 本研究的目的是描述HIV感染婴儿、儿童和青少年随时间推移的晚期结局，包括生存、生长、神经和神经心理功能、生活质量、器官系统毒性、代谢紊乱、机会性感染和恶性肿瘤的发生以及免疫学和病毒学参数。 这还将包括评价受试者接受的抗逆转录病毒和免疫治疗的潜在晚期结局、青春期影响以及并发症。 此外，确定艾滋病毒感染妇女所生的未感染婴儿是否因在子宫内、围产期或婴儿早期暴露于抗逆转录病毒治疗或免疫治疗/疫苗而表现出任何短期或长期不良临床或实验室影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To describe late outcomes over time in relation to survival, growth, neurologic, and neuropsychological function, quality of life, organ system toxicity, metabolic disorders, development of oppotunistic infections and malignancies, and immunologic, and virologic parameters in HIV-infected infants, children, and adolescents. This will also include evaluation of potential late effects, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. This study will also attempt to determine if uninfected infants born to HIV-infected women demonstrate any short or long-term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy. This is a perspective, longitudinal study for long term follow-up of perinatally HIV-exposed infants, children, and adolescents, and children with post-perinatally acquired infection followed at PACTG site regardless of whether they are enrolled in PACTG protocols. The purpose of this study is to describe late outcomes over time in relation to survival, growth, neurologic and neuropsychologic function, quality of life, organ system toxicity, metabolic disorders, development of opportunistic infections and malignancies, and immunilogical, and virologic parameters in HIV-infected infants, children and adolescents. This will also include evaluation of potential late outcomes, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. Moreover, to determine if uninfected infants born to HIV-infected women demonstrate any short or long term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy.